首页> 美国卫生研究院文献>AAPS PharmSciTech >Formulation and Release Behavior of Doxycycline–Alginate Hydrogel Microparticles Embedded into Pluronic F127 Thermogels as a Potential New Vehicle for Doxycycline Intradermal Sustained Delivery
【2h】

Formulation and Release Behavior of Doxycycline–Alginate Hydrogel Microparticles Embedded into Pluronic F127 Thermogels as a Potential New Vehicle for Doxycycline Intradermal Sustained Delivery

机译:强力霉素-海藻酸盐水凝胶微粒的配制和释放行为将其作为强力霉素皮内持续递送的潜在新载体嵌入Pluronic F127热凝胶

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this work was the formulation and characterization of alginate (ALG)–doxycycline (DOX) hydrogel microparticles (MPs) embedded into Pluronic F127 thermogel for DOX intradermal sustained delivery. ALG–DOX MPs were formed by adding a solution of the drug into a 1.5% polymer solution while stirring. The MPs were cross-linked by dispersion into a 1.2% CaCl2 solution. Free MPs were characterized in terms of size, drug content, and release behavior by HPLC and UV–vis. DOX and hydrogel MPs were embedded into PF127, PF127-HPMC, and PF127-Methocel thermogels. The thermogels were characterized in terms of gelling time, morphology, and release behavior. A target release period of 4–7 days was considered optimal. The hydrogel MPs were about 20 µm in size with 90% of the population <59 µm. Drug content was about 35% (w/w). DOX released rapidly from the MPs, 90% within 2 days. An expected faster release was observed for free DOX from the thermogels with 80–90% of drug released after 3.5–4 h even in the presence of 1% HPMC or Methocel. The release was sustained after embedding the MPs into PF127 and PF127-HPMC thermogels. In particular, the PF127-HPMC thermogel showed an almost linear release, reaching 80% after 3 days and 90% up to 6 days. Although a further characterization and formulation assessment is required to optimize MP characteristics, ALG/DOX-loaded hydrogel MPs, when embedded into a PF127-HPMC thermogel, show a potential for achieving a 7-day sustained release formulation for DOX intradermal delivery.
机译:这项工作的目的是配制和表征海藻酸盐(ALG)-强力霉素(DOX)水凝胶微粒(MPs),该微粒被嵌入Pluronic F127热凝胶中以进行DOX皮内持续​​递送。通过在搅拌的同时将药物溶液添加到1.5%的聚合物溶液中来形成ALG-DOX MP。通过分散到1.2%CaCl2溶液中使MP交联。通过HPLC和UV-vis对游离MP的大小,药物含量和释放行为进行了表征。将DOX和水凝胶MP嵌入PF127,PF127-HPMC和PF127-Methocel热凝胶中。根据胶凝时间,形态和释放行为来表征热凝胶。目标发布期为4-7天被认为是最佳的。水凝胶的MP大小约为20 µm,其中90%的人口<59 µm。药物含量为约35%(w / w)。 DOX在2天内迅速从MP中释放出来,达到90%。观察到从热凝胶中游离DOX的预期更快释放,甚至在存在1%HPMC或Methocel的情况下,在3.5-4小时后释放了80-90%的药物。将MP嵌入PF127和PF127-HPMC热凝胶后,该释放得以持续。尤其是PF127-HPMC热凝胶显示出几乎线性的释放,3天后达到80%,最多6天达到90%。尽管需要进一步的表征和配方评估以优化MP特性,但载有ALG / DOX的水凝胶MP嵌入PF127-HPMC热凝胶时,显示出可以实现7天的缓释配方用于DOX皮内递送的潜力。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号